Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 8/20 | 0.48 |
| ▸ | METAP2 | P50579 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cambendazole SCHEMBL44000 | 1.00 | METAP1 (0.48) | METAP1METAP2KDM4ENPC1RAB9A | |
| Cambendazole SCHEMBL8734398 | 0.95 | METAP1 (0.57) | METAP1METAP2KDM4ENPC1RAB9A | |
| Cambendazole SCHEMBL2895694 | 0.92 | METAP1 (0.55) | METAP1METAP2KDM4ENPC1RAB9A | |
| SCHEMBL3500748 | 0.89 | METAP1 (0.52) | METAP1METAP2KDM4ENPC1RAB9A | |
| Mebendazole SCHEMBL2406875 | 0.85 | METAP1 (0.54) | METAP1METAP2KDM4ENPC1RAB9A | |
| Diethenofencarb SCHEMBL9055860 | 0.84 | HPSE (0.51) | METAP1METAP2KDM4ENPC1RAB9A | |
| SCHEMBL11208569 | 0.83 | METAP1 (0.55) | METAP1METAP2KDM4ENPC1RAB9A | |
| SCHEMBL5190850 | 0.82 | TUBB4A (0.43) | KDM4ENPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4367982 | 0.81 | METAP1 (0.50) | METAP1METAP2KDM4ENPC1RAB9A | |
| SCHEMBL4366074 | 0.81 | METAP1 (0.50) | METAP1METAP2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| WO-2024118002-A1 | PHOTOBIOREACTOR SYSTEM FOR THE REDUCTION OF AMMONIA AND CARBON DIOXIDE GASES IN POULTRY HOUSES | BURSA ULUDAĞ ÜNİVERSİTESİ (TR) | 2024-06-06 | — | — | WO | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | claimed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-3253757-B1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024118002-A1 | PHOTOBIOREACTOR SYSTEM FOR THE REDUCTION OF AMMONIA AND CARBON DIOXIDE GASES IN POULTRY HOUSES | BURSA ULUDAĞ ÜNİVERSİTESİ (TR) | 2024-06-06 | — | — | WO | disclosed |
| EP-4055010-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | Bayer Aktiengesellschaft (DE) | 2022-09-14 | — | — | EP | disclosed |
| EP-4036083-A1 | 5-OXY SUBSTITUTED HETEROCYCLES AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| EP-4003966-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3765466-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3765465-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3615540-B1 | CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3974414-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PESTICIDES | Bayer AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022053453-A1 | AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | SI, PIM1, PIM3 | METAP1 4691/4885METAP2 4764/4885KDM4E 1216/4885 |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | METAP1 4691/4885METAP2 4764/4885KDM4E 1216/4885 |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | FABP1, POLRMT, LIPC | METAP1 1925/4885METAP2 1671/4885KDM4E 4795/4885 |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | NPC1L1, CYP46A1, PCSK9 | METAP1 1461/4885METAP2 1687/4885KDM4E 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.